ADMA Q2 2025 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$122M+13.8% YoY

Gross Profit

$67M55.1% margin

Operating Income

$43M35.1% margin

Net Income

$34M28.1% margin

EPS (Diluted)

$0.14

QoQ Revenue Growth

+6.3%

Cash Flow

Operating Cash Flow

$21M

Free Cash Flow

$19M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$558M

Total Liabilities

$160M

Stockholders' Equity

$398M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$122M	$107M	+13.8%
Gross Profit	$67M	$57M	+17.0%
Operating Income	$43M	$39M	+9.2%
Net Income	$34M	$32M	+6.7%

Geographic Segments

UNITED STATES

$122M100%